Thijs van Haaps/LinkedIn
Oct 29, 2025, 07:38
Thijs van Haaps and Team Show That Andexanet Alfa May Go Beyond Apixaban and Rivaroxaban
RPTH Journal shared a post on LinkedIn:
“New in RPTH!
Thijs van Haaps and team show that Andexanet alfa may go beyond apixaban and rivaroxaban—showing reversal potential for enoxaparin. In both healthy volunteers and bleeding patients, anti-Xa activity fell rapidly and 88% achieved good hemostasis.”
Title: Andexanet Alfa for the Reversal of the Low-Molecular-Weight Heparin Enoxaparin
Authors: Thijs F. van Haaps, Alexander P. Benz, Lizhen Xu, Saskia Middeldorp, John W. Eikelboom, Truman J. Milling, Jr., Mark Crowther, Lisa Holer, Stephan Nolan, Per Ladenvall, Genmin Lu, Michiel Coppens
Read more here.
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 09:29Advancing Women’s Health Through Collaboration with Jean Hailes for Women’s Health – Stroke Foundation
-
Jun 24, 2026, 09:18The Lasting Immunological Footprint of VITT – JTH
-
Jun 24, 2026, 09:09Umberto Pensato: Dedicated Funding Pathways for Stroke Research in Italy
-
Jun 24, 2026, 09:00Danny Gaskin: BBTS 2026 and the Evolving Role of Transfusion in Maternity Care
-
Jun 24, 2026, 07:46Wolfgang Miesbach: WFH’s First AAV Gene Therapy Chapter Marks a New Era in Hemophilia Care
-
Jun 24, 2026, 06:42Deepthi Krishna: World Blood Donor Day 2026 Celebrations at Rela Hospital
-
Jun 24, 2026, 03:36Ana Pedrero Gil: A New Approach to Post-Tonsillectomy Hemorrhage
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting